Why Aren't There Biomarkers For Mental Illness? - Science Friday Recap
Podcast: Science Friday
Published: 2026-02-23
Duration: 12 min
Guests: Dr. John Kristol
Summary
Despite advances in understanding mental health disorders, identifying biomarkers for conditions like depression and anxiety remains elusive due to the complexity of the brain and variability in symptoms.
What Happened
The episode dives into the challenges of identifying biomarkers for mental illness, highlighting the complexity of the brain and the current lack of direct diagnostic tools like blood tests or brain scans for psychiatric conditions. Dr. John Kristol explains that while precision medicine has advanced in other fields through tissue analysis, such approaches are not feasible in psychiatry due to the ethical and practical challenges of sampling brain tissue from living patients.
Dr. Kristol discusses ongoing research involving donated brain tissue, which has begun to reveal molecular signatures that could differentiate between conditions like PTSD and depression. However, the overlap and variability in symptoms across different mental health disorders make it difficult to pinpoint specific biomarkers.
The conversation touches on how mental health disorders like depression can manifest in diverse ways, with the DSM-5 outlining numerous criteria for diagnosis. This variability poses a significant challenge for researchers attempting to define precise biological markers.
Alzheimer's disease is highlighted as an example where successful biomarker identification has aided diagnosis and treatment, contrasting with the current state of psychiatric disorders. Dr. Kristol notes that Alzheimer's can be diagnosed using PET scans to detect chemical accumulations in the brain.
The promise of future psychiatric diagnosis is discussed, with hopes of achieving precision akin to that in breast cancer treatment. Current efforts involve genetic analysis, imaging techniques such as fMRI, and behavioral data to better understand and subtype psychiatric conditions.
Dr. Kristol elaborates on the genetic complexities of mental disorders, using schizophrenia as an example. While rare mutations significantly increase schizophrenia risk, most cases involve a combination of common genetic variants that contribute incrementally.
The episode concludes by reflecting on the aspirational nature of incorporating biomarkers into the DSM, recognizing that while the groundwork is being laid, widespread clinical application of these findings remains in the future.
Key Insights
- The identification of biomarkers for mental illnesses is challenging due to the ethical and practical difficulties of obtaining brain tissue samples from living patients, unlike other fields where tissue analysis is more feasible.
- Current research using donated brain tissue has started to identify molecular signatures that may differentiate psychiatric conditions like PTSD and depression, though symptom overlap complicates the search for specific biomarkers.
- Alzheimer's disease serves as a contrast to psychiatric disorders, as it can be diagnosed using PET scans to detect chemical accumulations in the brain, highlighting the lack of similar diagnostic tools for mental illnesses.
- Schizophrenia risk is influenced by a combination of rare mutations and common genetic variants, with most cases involving incremental contributions from multiple genes rather than a single causative factor.